At Comend, everything we do is rooted in one tenant: the rare disease community leads. Families, foundations, and advocates aren’t waiting—they’re building roadmaps, launching research, and pushing forward with urgency and heart. Our role is to support that momentum. To build bridges and help make the next step a little more possible.
That’s why we’re honored to officially share our partnership with Odylia Therapeutics, an organization that has long stood beside patient groups as they’ve taken research into their own hands. With deep experience in gene therapy and a track record of helping advocacy-led efforts succeed, Odylia has been the perfect partner to help shape Comend’s research marketplace.
Together, we’ve spent the last 9 months co-designing features that feel intuitive and approachable so that patient groups can more easily discover trusted service providers and collaborations that move their programs forward. Whether you're pursuing a zebrafish model, a tox study, or something entirely new, we hope this partnership makes the journey more connected and less overwhelming.
This partnership has been 9 months in the making but we finally get to officially announce it! We saw "The Odylia Collective" as a natural extension of Odylia Therapeutics' mission of 'accelerating therapeutic development for rare diseases' and I am very happy that we found such a wonderful partner in Comend to see the concept really take life and sprout wings 🪽! - Ashley Winslow, CEO/CSO of Odylia
We’re grateful to Ashley and the entire Odylia team for their shared vision and trust—and to every rare disease advocate who continues to shape how research is done.
This partnership is just the beginning. We’re so excited for what comes next.
👉 Read the full announcement here.